Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of 18F-AV-1451 kinetic modeling in Alzheimer's disease and healthy controls
2014-003047-35Phase 2Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Aug 2015
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of flortaucipir in Alzheimer's disease (AD) (2 arms), sponsored by Avid Radiopharmaceuticals. Primary endpoint: Pharmacokinetic tracer uptake model. Started Aug 2015; status: completed.
02
Drugs
flortaucipir
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2014-003047-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003047-35.